Related Experiment Video
Updated: Jun 29, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Anticoagulation in atrial fibrillation].
1Abteilung für Kardiologie und Angiologie, Universitätsklinikum Freiburg. meischwarz@yahoo.de
Hamostaseologie
|October 7, 2008
Summary
Effective anticoagulation is crucial for atrial fibrillation patients to prevent thrombotic events. Current therapies like vitamin-K antagonists and aspirin have limitations, prompting research into safer, more convenient alternatives.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Atrial fibrillation management necessitates effective anticoagulation to prevent thrombotic events.
- Current oral anticoagulants, vitamin-K antagonists (VKAs) and aspirin (ASA), present therapeutic challenges.
- VKAs offer efficacy but carry a high bleeding risk, while ASA provides moderate risk reduction with minimal side effects.
Purpose:
- To review current guideline recommendations for anticoagulation in atrial fibrillation.
- To discuss the limitations of existing anticoagulant therapies.
- To provide an outlook on emerging anticoagulant strategies.
Summary:
- Current atrial fibrillation guidelines recommend risk-stratified anticoagulation using tools like the CHADS2-Score.
- Vitamin-K antagonists and aspirin are the primary oral anticoagulants, each with distinct efficacy and safety profiles.
- Novel oral anticoagulants, including factor Xa and factor II inhibitors, are under investigation for improved safety and convenience.
Impact:
- Highlights the need for improved anticoagulation strategies in atrial fibrillation.
- Informs clinicians about the evolving landscape of anticoagulant therapies.
- Suggests future directions in preventing thrombotic events for atrial fibrillation patients.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...